Germline determinants of the prostate tumor genome

Kathleen E. Houlahan,Jiapei Yuan,Tommer Schwarz,Julie Livingstone,Natalie S. Fox,Weerachai Jaratlerdsiri,Job van Riet,Kodi Taraszka,Natalie Kurganovs,Helen Zhu,Jocelyn Sietsma Penington,Chol-Hee Jung,Takafumi N Yamaguchi,Jue Jiang,Lawrence E Heisler,Richard Jovelin,Susmita G Ramanand,Connor Bell,Edward O’Connor,Shingai B.A. Mutambirwa,Ji-Heui Seo,Anthony J. Costello,Mark M. Pomerantz,Bernard J. Pope,Noah Zaitlen,Amar U. Kishan,Niall M. Corcoran,Robert G. Bristow,Sebastian M. Waszak,Riana M.S. Bornman,Alexander Gusev,Martijn P. Lolkema,Joachim Weischenfeldt,Rayjean J. Hung,Housheng H. He,Vanessa M. Hayes,Bogdan Pasaniuc,Matthew L. Freedman,Christopher M. Hovens,Ram S. Mani,Paul C. Boutros

DOI: https://doi.org/10.1101/2022.11.16.516773

2022-01-01

Abstract:A person’s germline genome strongly influences their risk of developing cancer. Yet the molecular mechanisms linking the host genome to the specific somatic molecular phenotypes of individual cancers are largely unknown. We quantified the relationships between germline polymorphisms and somatic mutational features in prostate cancer. Across 1,991 prostate tumors, we identified 23 co-occurring germline and somatic events in close 2D or 3D spatial genomic proximity, affecting 10 cancer driver genes. These driver quantitative trait loci (dQTLs) overlap active regulatory regions, and shape the tumor epigenome, transcriptome and proteome. Some dQTLs are active in multiple cancer types, and information content analyses imply hundreds of undiscovered dQTLs. Specific dQTLs explain at least 16.7% ancestry-biases in rates of TMPRSS2-ERG gene fusions and 67.3% of ancestry-biases in rates of FOXA1 point mutations. These data reveal extensive influences of common germline variation on somatic mutational landscapes. ### Competing Interest Statement A.U.K. has received personal fees from Varian Medical Systems, Inc., ViewRay, Inc., Janssen, Inc., and Intelligent Automation, Inc. P.C.B. sits on the Scientific Advisory Boards of BioSymetrics Inc. and Intersect Diagnostics Inc. All other authors declare they have no conflicts of interest. At the time of publication, N.S.F was an employee of Hoffman-La Roche Limited (Roche Canada). All contributions by N.S.F were completed prior to this employment.